ADMA 바이올로직스(ADMA)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $9.11 (+1.79%), 시가총액 $1.97B, PER (주가수익비율) 14.12, 52주 최저~최고 $8.29 ~ $21.87.
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also de
ADMA 바이올로직스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
ADMA 바이올로직스의 현재 주가는 $9.11 (+1.79%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
ADMA 바이올로직스의 시가총액은 약 $1.97B입니다. PER은 14.12입니다.
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United